questionsmedicales.fr
Phénomènes génétiques
Structures génétiques
Génome
Composants de génome
Gènes
Composants de gène
Régions non traduites
Régions 3' non traduites
Régions 3' non traduites : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Régions 3' non traduites : Questions médicales les plus fréquentes",
"headline": "Régions 3' non traduites : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Régions 3' non traduites : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-03-30",
"dateModified": "2025-03-25",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Régions 3' non traduites"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Régions non traduites",
"url": "https://questionsmedicales.fr/mesh/D020506",
"about": {
"@type": "MedicalCondition",
"name": "Régions non traduites",
"code": {
"@type": "MedicalCode",
"code": "D020506",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G05.360.340.024.340.137.910"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Éléments riches en AU",
"alternateName": "AU Rich Elements",
"url": "https://questionsmedicales.fr/mesh/D063307",
"about": {
"@type": "MedicalCondition",
"name": "Éléments riches en AU",
"code": {
"@type": "MedicalCode",
"code": "D063307",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G05.360.340.024.340.137.910.880.500"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Régions 3' non traduites",
"alternateName": "3' Untranslated Regions",
"code": {
"@type": "MedicalCode",
"code": "D020413",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Fan Jiang",
"url": "https://questionsmedicales.fr/author/Fan%20Jiang",
"affiliation": {
"@type": "Organization",
"name": "Prenatal Diagnostic Center, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, People's Republic of China."
}
},
{
"@type": "Person",
"name": "Dong-Zhi Li",
"url": "https://questionsmedicales.fr/author/Dong-Zhi%20Li",
"affiliation": {
"@type": "Organization",
"name": "Prenatal Diagnostic Center, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, People's Republic of China."
}
},
{
"@type": "Person",
"name": "Kevin Struhl",
"url": "https://questionsmedicales.fr/author/Kevin%20Struhl",
"affiliation": {
"@type": "Organization",
"name": "Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, USA."
}
},
{
"@type": "Person",
"name": "Raffaella Liccardo",
"url": "https://questionsmedicales.fr/author/Raffaella%20Liccardo",
"affiliation": {
"@type": "Organization",
"name": "Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università di Napoli Federico II, 80131 Naples, Italy."
}
},
{
"@type": "Person",
"name": "Marina De Rosa",
"url": "https://questionsmedicales.fr/author/Marina%20De%20Rosa",
"affiliation": {
"@type": "Organization",
"name": "Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università di Napoli Federico II, 80131 Naples, Italy."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "ROP screening with the Pictor Plus camera: a telemedicine solution for developing countries.",
"datePublished": "2022-09-17",
"url": "https://questionsmedicales.fr/article/36126881",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jaapos.2022.05.019"
}
},
{
"@type": "ScholarlyArticle",
"name": "A Residual Fusion Network for Osteosarcoma MRI Image Segmentation in Developing Countries.",
"datePublished": "2022-08-03",
"url": "https://questionsmedicales.fr/article/35965771",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1155/2022/7285600"
}
},
{
"@type": "ScholarlyArticle",
"name": "Neurological outcomes in neonates treated with therapeutic hypothermia: challenges in a developing country.",
"datePublished": "2024-09-28",
"url": "https://questionsmedicales.fr/article/39341210",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1055/s-0044-1790575"
}
},
{
"@type": "ScholarlyArticle",
"name": "Modified Borggreve-Van Nes-Winkelmann rotationplasty for surgery in developing countries.",
"datePublished": "2022-09-07",
"url": "https://questionsmedicales.fr/article/36071411",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12893-022-01780-z"
}
},
{
"@type": "ScholarlyArticle",
"name": "Neurotrauma: a burgeoning, yet understudied disease of rural areas in developing countries.",
"datePublished": "2022-09-02",
"url": "https://questionsmedicales.fr/article/36057116",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3171/2022.7.JNS22996"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Phénomènes génétiques",
"item": "https://questionsmedicales.fr/mesh/D055614"
},
{
"@type": "ListItem",
"position": 3,
"name": "Structures génétiques",
"item": "https://questionsmedicales.fr/mesh/D040342"
},
{
"@type": "ListItem",
"position": 4,
"name": "Génome",
"item": "https://questionsmedicales.fr/mesh/D016678"
},
{
"@type": "ListItem",
"position": 5,
"name": "Composants de génome",
"item": "https://questionsmedicales.fr/mesh/D040481"
},
{
"@type": "ListItem",
"position": 6,
"name": "Gènes",
"item": "https://questionsmedicales.fr/mesh/D005796"
},
{
"@type": "ListItem",
"position": 7,
"name": "Composants de gène",
"item": "https://questionsmedicales.fr/mesh/D040461"
},
{
"@type": "ListItem",
"position": 8,
"name": "Régions non traduites",
"item": "https://questionsmedicales.fr/mesh/D020506"
},
{
"@type": "ListItem",
"position": 9,
"name": "Régions 3' non traduites",
"item": "https://questionsmedicales.fr/mesh/D020413"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Régions 3' non traduites - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Régions 3' non traduites",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-09",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Régions 3' non traduites",
"description": "Comment identifier les 3' UTR dans un gène ?\nQuels tests sont utilisés pour étudier les 3' UTR ?\nLes 3' UTR sont-ils visibles sur des électrophorèses ?\nPeut-on détecter des mutations dans les 3' UTR ?\nQuel rôle jouent les 3' UTR dans le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D020413?mesh_terms=Developing+Countries&page=5#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Régions 3' non traduites",
"description": "Les 3' UTR sont-ils associés à des symptômes cliniques ?\nQuels symptômes peuvent résulter de mutations dans les 3' UTR ?\nLes 3' UTR affectent-ils la réponse aux traitements ?\nY a-t-il des symptômes spécifiques liés aux 3' UTR ?\nLes 3' UTR peuvent-ils être impliqués dans des syndromes ?",
"url": "https://questionsmedicales.fr/mesh/D020413?mesh_terms=Developing+Countries&page=5#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Régions 3' non traduites",
"description": "Peut-on prévenir les maladies liées aux 3' UTR ?\nQuels conseils pour réduire les risques liés aux 3' UTR ?\nLes antécédents familiaux influencent-ils la prévention ?\nY a-t-il des programmes de prévention pour les 3' UTR ?\nComment le mode de vie affecte-t-il les 3' UTR ?",
"url": "https://questionsmedicales.fr/mesh/D020413?mesh_terms=Developing+Countries&page=5#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Régions 3' non traduites",
"description": "Comment traiter les maladies liées aux 3' UTR ?\nLes thérapies ciblées affectent-elles les 3' UTR ?\nPeut-on modifier les 3' UTR pour traiter des maladies ?\nLes traitements peuvent-ils influencer les 3' UTR ?\nY a-t-il des médicaments ciblant les 3' UTR ?",
"url": "https://questionsmedicales.fr/mesh/D020413?mesh_terms=Developing+Countries&page=5#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Régions 3' non traduites",
"description": "Quelles complications peuvent survenir avec les 3' UTR ?\nLes 3' UTR sont-ils liés à des cancers ?\nComment les 3' UTR affectent-ils la santé ?\nLes complications des 3' UTR sont-elles héréditaires ?\nY a-t-il des complications neurologiques liées aux 3' UTR ?",
"url": "https://questionsmedicales.fr/mesh/D020413?mesh_terms=Developing+Countries&page=5#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Régions 3' non traduites",
"description": "Quels facteurs de risque sont associés aux 3' UTR ?\nL'environnement influence-t-il les 3' UTR ?\nLes habitudes de vie impactent-elles les 3' UTR ?\nLes mutations dans les 3' UTR sont-elles fréquentes ?\nY a-t-il des tests pour évaluer les risques liés aux 3' UTR ?",
"url": "https://questionsmedicales.fr/mesh/D020413?mesh_terms=Developing+Countries&page=5#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment identifier les 3' UTR dans un gène ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les 3' UTR peuvent être identifiés par séquençage d'ARN et analyses bioinformatiques."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour étudier les 3' UTR ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests incluent le RT-PCR et les analyses de microarrays pour évaluer l'expression."
}
},
{
"@type": "Question",
"name": "Les 3' UTR sont-ils visibles sur des électrophorèses ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, les 3' UTR ne sont pas visibles directement sur les gels d'électrophorèse."
}
},
{
"@type": "Question",
"name": "Peut-on détecter des mutations dans les 3' UTR ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des mutations dans les 3' UTR peuvent être détectées par séquençage ciblé."
}
},
{
"@type": "Question",
"name": "Quel rôle jouent les 3' UTR dans le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent influencer la stabilité de l'ARN et l'expression des gènes, affectant le diagnostic."
}
},
{
"@type": "Question",
"name": "Les 3' UTR sont-ils associés à des symptômes cliniques ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Indirectement, des anomalies dans les 3' UTR peuvent entraîner des symptômes par régulation génique."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent résulter de mutations dans les 3' UTR ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des mutations peuvent causer des maladies génétiques, entraînant divers symptômes."
}
},
{
"@type": "Question",
"name": "Les 3' UTR affectent-ils la réponse aux traitements ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent influencer la réponse aux traitements en modifiant l'expression des gènes."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes spécifiques liés aux 3' UTR ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, les symptômes sont généralement liés à des maladies spécifiques, pas aux 3' UTR eux-mêmes."
}
},
{
"@type": "Question",
"name": "Les 3' UTR peuvent-ils être impliqués dans des syndromes ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des syndromes génétiques peuvent être associés à des mutations dans les 3' UTR."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les maladies liées aux 3' UTR ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention est difficile, mais un dépistage génétique peut aider à identifier les risques."
}
},
{
"@type": "Question",
"name": "Quels conseils pour réduire les risques liés aux 3' UTR ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Adopter un mode de vie sain et se soumettre à des tests génétiques si nécessaire."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux influencent-ils la prévention ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de maladies génétiques peuvent augmenter le risque."
}
},
{
"@type": "Question",
"name": "Y a-t-il des programmes de prévention pour les 3' UTR ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des programmes de sensibilisation et de dépistage génétique existent pour certaines maladies."
}
},
{
"@type": "Question",
"name": "Comment le mode de vie affecte-t-il les 3' UTR ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sain peut influencer l'expression génique, y compris celle des 3' UTR."
}
},
{
"@type": "Question",
"name": "Comment traiter les maladies liées aux 3' UTR ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement dépend de la maladie sous-jacente, souvent par thérapies géniques ou médicamenteuses."
}
},
{
"@type": "Question",
"name": "Les thérapies ciblées affectent-elles les 3' UTR ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines thérapies ciblées peuvent moduler l'expression des gènes via les 3' UTR."
}
},
{
"@type": "Question",
"name": "Peut-on modifier les 3' UTR pour traiter des maladies ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des approches de modification des 3' UTR sont en recherche pour traiter certaines maladies."
}
},
{
"@type": "Question",
"name": "Les traitements peuvent-ils influencer les 3' UTR ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains traitements peuvent affecter la régulation des 3' UTR et l'expression génique."
}
},
{
"@type": "Question",
"name": "Y a-t-il des médicaments ciblant les 3' UTR ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, peu de médicaments ciblent spécifiquement les 3' UTR, mais la recherche progresse."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec les 3' UTR ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications peuvent inclure des maladies génétiques et des troubles de l'expression génique."
}
},
{
"@type": "Question",
"name": "Les 3' UTR sont-ils liés à des cancers ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des altérations dans les 3' UTR peuvent être associées à certains types de cancers."
}
},
{
"@type": "Question",
"name": "Comment les 3' UTR affectent-ils la santé ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils régulent l'expression des gènes, et des anomalies peuvent entraîner des problèmes de santé."
}
},
{
"@type": "Question",
"name": "Les complications des 3' UTR sont-elles héréditaires ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être héréditaires, selon les mutations présentes dans les 3' UTR."
}
},
{
"@type": "Question",
"name": "Y a-t-il des complications neurologiques liées aux 3' UTR ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines mutations dans les 3' UTR peuvent être associées à des troubles neurologiques."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque sont associés aux 3' UTR ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents familiaux, des mutations génétiques et des environnements spécifiques."
}
},
{
"@type": "Question",
"name": "L'environnement influence-t-il les 3' UTR ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des facteurs environnementaux peuvent affecter l'expression des gènes régulés par les 3' UTR."
}
},
{
"@type": "Question",
"name": "Les habitudes de vie impactent-elles les 3' UTR ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines habitudes de vie, comme le tabagisme, peuvent influencer l'expression des 3' UTR."
}
},
{
"@type": "Question",
"name": "Les mutations dans les 3' UTR sont-elles fréquentes ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les mutations dans les 3' UTR sont moins fréquentes que dans les régions codantes, mais significatives."
}
},
{
"@type": "Question",
"name": "Y a-t-il des tests pour évaluer les risques liés aux 3' UTR ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des tests génétiques peuvent évaluer les risques associés aux mutations dans les 3' UTR."
}
}
]
}
]
}
To assess the Pictor Plus portable noncontact ophthalmic camera for use in diagnosis of severe retinopathy of prematurity (ROP) and its feasibility for telemedicine applications, especially in develop...
A cross-sectional study was conducted from April 2018 to December 2019 in six public neonatal care centers in the state of Rio de Janeiro. Observer 1 performed the examination with a binocular indirec...
The convenience sample was 200 premature newborns (n = 712 eyes) with a birthweight of ≤1,500 g or gestational age at birth of ≤32 weeks. The sensitivity of Pictor Plus digital images for the diagnosi...
In our study cohort, the Pictor Plus, a relatively low-cost camera, was effective in facilitating accurate diagnosis of ROP....
Among primary bone cancers, osteosarcoma is the most common, peaking between the ages of a child's rapid bone growth and adolescence. The diagnosis of osteosarcoma requires observing the radiological ...
Hypoxic-ischemic encephalopathy (HIE) affects 1.5 newborns per 1 thousand term live births. Therapeutic hypothermia (TH) does not prevent all adverse outcomes. The experience with TH is still limited ...
To describe the frequency of epilepsy, altered neurological exam, and neurodevelopmental delay at 12 months of age in patients treated with TH in a reference hospital in Rio de Janeiro and to evaluate...
We evaluated medical records from the Neonatal Intensive Care Unit hospitalization and from first evaluation recorded at 12 months of age in the High-Risk Neonate Follow-up Outpatient Sevice....
A total of 30 subjects were included in the study. We found epilepsy in 18.2% of the patients, altered neurological exam in 40.9%, and neurodevelopmental delay in 36.4%. We also found a significant re...
High incidences of epilepsy, altered neurological exams, and neurodevelopmental delay were found, despite the use of TH. A more efficient use of resources is needed, as well as measures such as early ...
Amputation is still the most common therapy for patients suffering from osteosarcoma in Myanmar, despite the fact that limb salvage surgery e.g. Borggreve-Van Nes-Winkelmann rotationplasty for maligna...
From 2019 until 2020, seven young patients with osteosarcomas of the distal femur or proximal tibia were treated with Borggreve-Van Nes-Winkelmann rotationplasties in the Orthopaedic Hospital in Manda...
All patients showed good functional and aesthetic results. One of the seven patients needed secondary wound closure due to wound dehiscence....
A simplified and safe operation technique for the performance of the Van Nes-Borggreve rotationplasty was adapted to the given constraints in lower-middle income economies and proved to be successful....
There is a paucity of data-driven reports on neurotrauma from the rural areas of developing countries, despite a disproportionally higher and burgeoning disease burden from those areas. This study aim...
The authors conducted a prospective observational study of all neurotrauma patients managed at their center over a 36-month period beginning in August 2018....
There were 1067 patients, 816 (76.5%) of them male, accounting for 79% of all the neurosurgical patients seen at the authors' center during the study period. The peak incidence of neurotrauma was in t...
Neurotrauma, mostly caused by motorcycle crashes and other road accidents, accounts for the bulk of the neurosurgical workload in this rural neurosurgical center. Although late presentation and delaye...
Antifungal stewardship is a less explored component of antimicrobial stewardship programmes, especially in developing countries....
We aimed to determine antifungal prescription practices in a tertiary centre of a developing country to identify the challenges for antifungal stewardship programmes....
Four single-day point prevalent surveys were performed in inpatient units and data were collected from medical records. Antifungal use was recorded in terms of consumption, therapeutic strategies and ...
We found a 2.42%-point prevalence of antifungal prescriptions. Antifungal use was higher in children than adults (4.1% vs. 2.03%), medical than surgical units (3.7% vs. 1.24%) and ICUs than general wa...
We report here the low prevalence of antifungal use at a tertiary care centre in a developing country. Though training for antifungal use would be important for antifungal stewardship, the challenge w...
This study delves into the intricate relationship between financial development and environmental sustainability by considering the role of the Paris Agreement in the context of developing countries. ...
Every Newborn Action Plan (ENAP) coverage target 4 necessitates national scale-up of Level-2 Small and Sick Newborn Care (SSNC) (with Continuous Positive Airway Pressure (CPAP)) in 80% of districts by...
A three-step systematic framework was used to review, co-design, and operationalise this novel neonatal inpatient dataset in four countries (Malawi, Kenya, Tanzania, and Nigeria) implementing with the...
Identified national and international datasets (n = 6) contained a median of 89 (IQR:61-154) variables, with many relating to research-specific initiatives. Maternal antenatal/intrapartum history was ...
The NEST360 NID is a novel, parsimonious tool for use in routine information systems to inform inpatient SSNC quality. Available on the NEST360/United Nations Children's Fund (UNICEF) Implementation T...
Given the importance of ICT diffusion in the development of the financial sector, this analysis is an effort to analyze the transmission channels between the two in high-income and middle and low-inco...
Recent years have witnessed a dramatic increase in debt servicing for developing countries. Drawing on the theoretical insights of dependency theory, I investigate the relationship between debt depend...